Developer docs
API playgroundTry for free, no card

Search company profiles

Creative Biolabs

Full company profile

uuid0006ft8

Namestring
Creative Biolabs
Legal namestring
Creative Biolabs
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Creative Biolabs is a private contract research organization (CRO) founded in 2014 and headquartered in Shirley, New York, that provides custom antibody discovery, engineering, characterization, and biomanufacturing services to pharmaceutical, biotechnology, and academic clients. The company serves a global customer base concentrated in North America and Europe, with two primary segments (pharma/biotech companies building antibody pipelines and academic/research institutions requiring reagents and platforms) and two secondary segments (cell and gene therapy developers and neuroscience-focused researchers). The firm has scaled to approximately 51-100 employees, roughly 100 service points, and a customer base whose work has been cited in 294 peer-reviewed articles or patents.

The company operates a portfolio of more than 18 proprietary platforms that span the antibody development continuum. Antibody discovery is anchored by Hyperdoma™ (electrofusion-based high-throughput hybridoma delivering 10³-10⁴ positive clones per fusion), Hi-Affi Hybridoma™ (50-200 clones per fusion via Magic Mouse Adjuvant), Hi-Affi™ phage display libraries with 10^10-10^12 independent clone diversity, yeast display, single B cell sorting, and transgenic mice. Engineering and characterization tools include Afuco™ for ADCC-enhanced non-fucosylated antibodies, iCrea™ standardized reporter cell lines, active antigen clearance with pH-dependent half-life extension, an Fc Silent platform for autoimmune applications, and AI-driven bispecific design achieving >90% heterodimerization efficiency. Adjacent platforms include NeuroST™ (3D neural organoids plus gene editing and microfluidics), LipoDrive™ (microfluidics-based liposome manufacturing), LNP platforms with 3x gene knockdown gains, GMP CAR-T solutions, oncolytic virus construction (adenoviral and HSV), circRNA analysis, and an end-to-end biosimilar CDMO offering. A notable technical specialization is expression and stabilization of difficult membrane protein targets (GPCRs, ion channels, transporters) under the MemDX™ banner.

Creative Biolabs generates revenue through two streams: project-based contract research services sold to enterprise clients via direct engagement with 24/7 scientific support, and product sales of ready-to-use items (phage and yeast display library kits, recombinant antibodies, membrane proteins, stable cell lines, ADC products) through its online catalog. Pricing is custom and quote-based; no standard tiers are disclosed. GTM combines 24/7 consultative sales, content marketing via the company blog, and active participation in major industry conferences (PEGS, World ADC, Antibody Engineering & Therapeutics, IO360, WRIB, Yale Innovation Summit, NIH Vendor Expo). The company holds ISO 9001:2015 certification for its quality management system.

Short descriptiontext

Creative Biolabs is a private contract research organization based in Shirley, NY providing custom antibody discovery, engineering, characterization, and biomanufacturing services to pharmaceutical, biotech, and academic clients globally. The firm operates proprietary platforms spanning phage display, hybridoma, bispecific engineering, CAR-T, and lipid-based drug delivery.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody discovery services, contract research organization, bispecific antibody engineering, membrane protein production, CAR-T cell therapy
Industry7 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Services (Antibody Discovery & Biologics)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

Creative Biolabs operates as a contract research organization providing custom biotechnology and pharmaceutical services. The company offers a comprehensive suite of services including antibody discovery, characterization, engineering, and manufacturing. Revenue is generated through project-based contracts with pharmaceutical companies, biotech firms, and academic institutions requiring specialized research services.

creative-biolabs.com:443
2Product Sales
TypeOne Time License
Description

The company sells ready-to-use products including phage display library kits, yeast display library kits, recombinant antibodies, membrane proteins, stable cell lines, and VLP products for research applications.

creative-biolabs.com:443
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 8 records shown
1NeuroST™
Description

Advanced 3D organoid platform for neurological disease research and drug discovery using gene editing, microfluidic technology, and detailed analytical tests.

einpresswire.com
+7 more records
Core offering1 text field

Creative Biolabs is a contract research organization (CRO) that delivers custom antibody discovery, engineering, characterization, and manufacturing services for pharmaceutical, biotechnology, and academic clients. The company offers proprietary platforms spanning phage display, hybridoma (Hyperdoma™, Hi-Affi Hybridoma™), yeast display, single B cell sorting, and transgenic mice systems to generate monoclonal, bispecific, and single domain antibodies, complemented by gene therapy, cell therapy, viral vector, biosimilar, and lipid nanoparticle delivery services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • Up to 10³ to 10⁴ positive clones per hybridoma fusion
+9 more records
Product overview1 text field

Creative Biolabs is a contract research organization (CRO) providing custom biotechnology and pharmaceutical services. The company offers an integrated platform of antibody discovery services including phage display, yeast display, hybridoma technology (Hyperdoma™ and Hi-Affi Hybridoma™), single B cell sorting, and transgenic mice platforms. Their service portfolio spans antibody engineering (humanization, Fc engineering via Afuco™ technology, iCrea™ cell lines), bispecific antibody development, CAR-T therapy development (including GMP manufacturing and artificial T-cell stimulation platforms), gene therapy (viral vectors, oncolytic viruses, circRNA platforms), and bioconjugation/LNP delivery platforms. They provide comprehensive virus-like particle production across multiple expression systems, biosimilar development and CDMO services, and a wide range of research products including recombinant antibodies, membrane proteins, stable cell lines, and phage/yeast display library kits. Their recent launches include NeuroST™ for neurological disease research, LipoDrive™ for liposome manufacturing, and lipid-based drug delivery platforms (Ethosomes, Transfersomes, Transethosomes). The company operates specialized platforms for membrane protein discovery, antibody characterization, and functional analysis to support drug discovery from early discovery through preclinical development.

Product and service18 records
1Antibody Discovery Services
CategoryAntibody Discovery Service
Description

Comprehensive custom services for de novo antibody discovery using phage display, yeast display, hybridoma, single B cell sorting, and transgenic mice platforms, for pharmaceutical, biotech, and academic clients.

2Antibody Engineering Services
CategoryAntibody Engineering Service
Description

Custom antibody humanization, caninization, camelization, simianization, murinization, Fc engineering, and affinity maturation services for therapeutic antibody optimization.

3Antibody Characterization Services
CategoryAntibody Characterization Service
Description

Binding, sequence, immunogenicity, and functional characterization services including affinity measurement, epitope mapping, paratope mapping, and specificity profiling.

4Membrane Protein Production Services
CategoryMembrane Protein Service
Description

Custom expression, stabilization, and preparation of difficult membrane protein targets including GPCRs, ion channels, and transporters for drug discovery research.

5Virus-Like Particle (VLP) Production Services
CategoryBioproduction Service
Description

Custom VLP production services across E. coli, yeast, insect cell, mammalian cell, and plant cell expression systems for vaccine and drug delivery research.

6Bispecific Antibody Development Services
CategoryBispecific Antibody Service
Description

End-to-end bispecific antibody development services integrating AI-driven design with proprietary engineering platforms (Charge Pair and Orthogonal Fab interfaces) for next-generation immunotherapy.

7GMP CAR-T Development Solutions
CategoryCell Therapy Manufacturing Service
Description

GMP-grade product and viral vector manufacturing solutions for CAR-T cell therapy development, supporting clinical production and viral vector design at the New York GMP facility.

8Oncolytic Virus Construction Services
CategoryGene Therapy Service
Description

Custom construction and optimization of adenoviral and herpes simplex virus (HSV) oncolytic vectors for precision oncology applications.

9Bioconjugation and Lipid Nanoparticle (LNP) Delivery Services
CategoryDrug Delivery Service
Description

Custom bioconjugation and lipid nanoparticle (LNP) delivery platforms with refined linker chemistry and conjugation sites for antibody-siRNA conjugates and gene therapy research.

10Biosimilar Development and CDMO Services
CategoryCDMO Service
Description

End-to-end biosimilar development and CDMO services covering molecular design through large-scale production for monoclonal antibodies and viral vectors, with advanced characterization capabilities.

11Human In Vitro Neuro Research Models
CategoryNeuroscience Research Service
Description

Human iPSC-derived neural models, microglia phagocytosis assays, and organ-on-chip platforms for preclinical neuro drug discovery, neuroinflammatory response evaluation, and blood-brain barrier dynamics studies.

12Phage Display Library Kits
CategoryCatalog Research Product
Description

Ready-to-use phage display library kits for direct screening of target-specific binders, available through the company online catalog.

13Yeast Display Library Kits
CategoryCatalog Research Product
Description

Ready-to-use yeast display library kits for binder discovery and protein engineering research applications.

14Premade Antibody and Peptide Libraries
CategoryCatalog Research Product
Description

Premade antibody and peptide libraries available for licensing or direct screening in binder discovery workflows.

15Recombinant Antibodies
CategoryCatalog Research Product
Description

Catalog recombinant antibody products including those against GPCRs, transporters, ion channels, CAR-T targets, biomarkers, and CD proteins.

16Membrane Protein Products
CategoryCatalog Research Product
Description

Catalog membrane protein products including GPCRs, ion channels, transporters, Fc receptors, HLA proteins, and MP-VLPs.

17Membrane Protein Stable Cell Lines
CategoryCatalog Research Product
Description

Stable cell lines overexpressing membrane proteins including GPCRs, ion channels, immune checkpoints, and oncology targets for screening applications.

18Antibody-Drug Conjugate (ADC) Products
CategoryCatalog Research Product
Description

Catalog antibody-drug conjugate (ADC) research products for cancer therapy development applications.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

GenScript is a leading CRO/CDMO offering custom antibody discovery, gene synthesis, protein engineering, and cell therapy services. It is the closest direct peer to Creative Biolabs given its overlapping focus on antibody/phage display platforms and custom research services for pharma and academic clients.

TypeDirect peer
Description

Abcam is a major provider of research-grade antibodies, recombinant antibodies, and antibody-related services with strong catalog offerings comparable to Creative Biolabs' recombinant antibody and membrane protein product lines. Both serve academic and pharma researchers globally.

TypeDirect peer
Description

Sino Biological provides recombinant proteins, antibodies, and CRO services for life science research, with a strong catalog of recombinant antibodies and membrane protein reagents. It overlaps with Creative Biolabs in membrane protein targets, recombinant antibody products, and custom services.

TypeBroad incumbent
Description

Bio-Techne is a large life science tools company offering proteins, antibodies, and reagents across research and diagnostics. While broader and more catalog-focused than Creative Biolabs, it competes in antibody reagents and protein-based services for the same buyer segments.

TypeBroad incumbent
Description

WuXi AppTec is a global CRO/CDMO with extensive capabilities spanning discovery, preclinical, and clinical services for biologics and small molecules. It is a much larger incumbent that competes with Creative Biolabs on antibody discovery and biologics manufacturing services.

TypeBroad incumbent
Description

Charles River Laboratories is a major CRO offering discovery, safety assessment, and manufacturing services including biologics and cell therapy support. It competes broadly with Creative Biolabs' preclinical CRO services and CDMO offerings.

TypeBroad incumbent
Description

Lonza is a leading global CDMO with biologics and cell/gene therapy manufacturing capabilities. Its GMP manufacturing and viral vector production overlap directly with Creative Biolabs' emerging GMP CAR-T and viral vector services.

TypeEmerging player
Description

ProMab is a smaller CRO specializing in custom monoclonal antibody development, hybridoma, and recombinant antibody services. It is an emerging peer competing directly in the same niche custom antibody discovery market as Creative Biolabs.

TypeBroad incumbent
Description

Cell Signaling Technology is an established antibody reagent company with strong catalog offerings for signaling and post-translational modification targets. It overlaps with Creative Biolabs' antibody catalog and PTM-specific antibody discovery services.

TypeBroad incumbent
Description

Thermo Fisher is the largest life sciences tools and CRO/CDMO provider through Patheon and PPD, offering end-to-end services from discovery through clinical manufacturing. It is a broad incumbent peer competing across Creative Biolabs' service categories.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature18 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Creative Biolabs

Contract Research Services (Antibody Discovery & Biologics)creative-biolabs.com

Creative Biolabs is a private contract research organization based in Shirley, NY providing custom antibody discovery, engineering, characterization, and biomanufacturing services to pharmaceutical, biotech, and academic clients globally. The firm operates proprietary platforms spanning phage display, hybridoma, bispecific engineering, CAR-T, and lipid-based drug delivery.

What Creative Biolabs does

Creative Biolabs is a private contract research organization (CRO) founded in 2014 and headquartered in Shirley, New York, that provides custom antibody discovery, engineering, characterization, and biomanufacturing services to pharmaceutical, biotechnology, and academic clients. The company serves a global customer base concentrated in North America and Europe, with two primary segments (pharma/biotech companies building antibody pipelines and academic/research institutions requiring reagents and platforms) and two secondary segments (cell and gene therapy developers and neuroscience-focused researchers). The firm has scaled to approximately 51-100 employees, roughly 100 service points, and a customer base whose work has been cited in 294 peer-reviewed articles or patents.

The company operates a portfolio of more than 18 proprietary platforms that span the antibody development continuum. Antibody discovery is anchored by Hyperdoma™ (electrofusion-based high-throughput hybridoma delivering 10³-10⁴ positive clones per fusion), Hi-Affi Hybridoma™ (50-200 clones per fusion via Magic Mouse Adjuvant), Hi-Affi™ phage display libraries with 10^10-10^12 independent clone diversity, yeast display, single B cell sorting, and transgenic mice. Engineering and characterization tools include Afuco™ for ADCC-enhanced non-fucosylated antibodies, iCrea™ standardized reporter cell lines, active antigen clearance with pH-dependent half-life extension, an Fc Silent platform for autoimmune applications, and AI-driven bispecific design achieving >90% heterodimerization efficiency. Adjacent platforms include NeuroST™ (3D neural organoids plus gene editing and microfluidics), LipoDrive™ (microfluidics-based liposome manufacturing), LNP platforms with 3x gene knockdown gains, GMP CAR-T solutions, oncolytic virus construction (adenoviral and HSV), circRNA analysis, and an end-to-end biosimilar CDMO offering. A notable technical specialization is expression and stabilization of difficult membrane protein targets (GPCRs, ion channels, transporters) under the MemDX™ banner.

Creative Biolabs generates revenue through two streams: project-based contract research services sold to enterprise clients via direct engagement with 24/7 scientific support, and product sales of ready-to-use items (phage and yeast display library kits, recombinant antibodies, membrane proteins, stable cell lines, ADC products) through its online catalog. Pricing is custom and quote-based; no standard tiers are disclosed. GTM combines 24/7 consultative sales, content marketing via the company blog, and active participation in major industry conferences (PEGS, World ADC, Antibody Engineering & Therapeutics, IO360, WRIB, Yale Innovation Summit, NIH Vendor Expo). The company holds ISO 9001:2015 certification for its quality management system.

Creative Biolabs firmographics

Firmographics
Name
Creative Biolabs
Legal name
Creative Biolabs
Website
https://creative-biolabs.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Creative Biolabs is a private contract research organization based in Shirley, NY providing custom antibody discovery, engineering, characterization, and biomanufacturing services to pharmaceutical, biotech, and academic clients globally. The firm operates proprietary platforms spanning phage display, hybridoma, bispecific engineering, CAR-T, and lipid-based drug delivery.
Ownership category
akta.pro rank

Creative Biolabs industry classification

Industry
Product category
Contract Research Services (Antibody Discovery & Biologics)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Antibody discovery services
  • Contract research organization
  • Bispecific antibody engineering
  • Membrane protein production
  • CAR-T cell therapy

Where Creative Biolabs is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Creative Biolabs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Research Services (CRO): Creative Biolabs operates as a contract research organization providing custom biotechnology and pharmaceutical services. The company offers a comprehensive suite of services including antibody discovery, characterization, engineering, and manufacturing. Revenue is generated through project-based contracts with pharmaceutical companies, biotech firms, and academic institutions requiring specialized research services.
  2. Product Sales: The company sells ready-to-use products including phage display library kits, yeast display library kits, recombinant antibodies, membrane proteins, stable cell lines, and VLP products for research applications.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Creative Biolabs product offering

Product offering

Core offering

Creative Biolabs is a contract research organization (CRO) that delivers custom antibody discovery, engineering, characterization, and manufacturing services for pharmaceutical, biotechnology, and academic clients. The company offers proprietary platforms spanning phage display, hybridoma (Hyperdoma™, Hi-Affi Hybridoma™), yeast display, single B cell sorting, and transgenic mice systems to generate monoclonal, bispecific, and single domain antibodies, complemented by gene therapy, cell therapy, viral vector, biosimilar, and lipid nanoparticle delivery services.

Product overview

Creative Biolabs is a contract research organization (CRO) providing custom biotechnology and pharmaceutical services. The company offers an integrated platform of antibody discovery services including phage display, yeast display, hybridoma technology (Hyperdoma™ and Hi-Affi Hybridoma™), single B cell sorting, and transgenic mice platforms. Their service portfolio spans antibody engineering (humanization, Fc engineering via Afuco™ technology, iCrea™ cell lines), bispecific antibody development, CAR-T therapy development (including GMP manufacturing and artificial T-cell stimulation platforms), gene therapy (viral vectors, oncolytic viruses, circRNA platforms), and bioconjugation/LNP delivery platforms. They provide comprehensive virus-like particle production across multiple expression systems, biosimilar development and CDMO services, and a wide range of research products including recombinant antibodies, membrane proteins, stable cell lines, and phage/yeast display library kits. Their recent launches include NeuroST™ for neurological disease research, LipoDrive™ for liposome manufacturing, and lipid-based drug delivery platforms (Ethosomes, Transfersomes, Transethosomes). The company operates specialized platforms for membrane protein discovery, antibody characterization, and functional analysis to support drug discovery from early discovery through preclinical development.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroST™: Advanced 3D organoid platform for neurological disease research and drug discovery using gene editing, microfluidic technology, and detailed analytical tests.
  • Hyperdoma™
  • Hi-Affi Hybridoma™
  • LipoDrive™
  • Afuco™
  • iCrea™
  • Hi-Affinity™
  • MemDX™

Products and services

  • Antibody Discovery Services Comprehensive custom services for de novo antibody discovery using phage display, yeast display, hybridoma, single B cell sorting, and transgenic mice platforms, for pharmaceutical, biotech, and academic clients.
  • Antibody Engineering Services Custom antibody humanization, caninization, camelization, simianization, murinization, Fc engineering, and affinity maturation services for therapeutic antibody optimization.
  • Antibody Characterization Services Binding, sequence, immunogenicity, and functional characterization services including affinity measurement, epitope mapping, paratope mapping, and specificity profiling.
  • Membrane Protein Production Services Custom expression, stabilization, and preparation of difficult membrane protein targets including GPCRs, ion channels, and transporters for drug discovery research.
  • Virus-Like Particle (VLP) Production Services Custom VLP production services across E. coli, yeast, insect cell, mammalian cell, and plant cell expression systems for vaccine and drug delivery research.
  • Bispecific Antibody Development Services End-to-end bispecific antibody development services integrating AI-driven design with proprietary engineering platforms (Charge Pair and Orthogonal Fab interfaces) for next-generation immunotherapy.
  • GMP CAR-T Development Solutions GMP-grade product and viral vector manufacturing solutions for CAR-T cell therapy development, supporting clinical production and viral vector design at the New York GMP facility.
  • Oncolytic Virus Construction Services Custom construction and optimization of adenoviral and herpes simplex virus (HSV) oncolytic vectors for precision oncology applications.
  • Bioconjugation and Lipid Nanoparticle (LNP) Delivery Services Custom bioconjugation and lipid nanoparticle (LNP) delivery platforms with refined linker chemistry and conjugation sites for antibody-siRNA conjugates and gene therapy research.
  • Biosimilar Development and CDMO Services End-to-end biosimilar development and CDMO services covering molecular design through large-scale production for monoclonal antibodies and viral vectors, with advanced characterization capabilities.
  • Human In Vitro Neuro Research Models Human iPSC-derived neural models, microglia phagocytosis assays, and organ-on-chip platforms for preclinical neuro drug discovery, neuroinflammatory response evaluation, and blood-brain barrier dynamics studies.
  • Phage Display Library Kits Ready-to-use phage display library kits for direct screening of target-specific binders, available through the company online catalog.
  • Yeast Display Library Kits Ready-to-use yeast display library kits for binder discovery and protein engineering research applications.
  • Premade Antibody and Peptide Libraries Premade antibody and peptide libraries available for licensing or direct screening in binder discovery workflows.
  • Recombinant Antibodies Catalog recombinant antibody products including those against GPCRs, transporters, ion channels, CAR-T targets, biomarkers, and CD proteins.
  • Membrane Protein Products Catalog membrane protein products including GPCRs, ion channels, transporters, Fc receptors, HLA proteins, and MP-VLPs.
  • Membrane Protein Stable Cell Lines Stable cell lines overexpressing membrane proteins including GPCRs, ion channels, immune checkpoints, and oncology targets for screening applications.
  • Antibody-Drug Conjugate (ADC) Products Catalog antibody-drug conjugate (ADC) research products for cancer therapy development applications.

Quantifiable outcome

  • Up to 10³ to 10⁴ positive clones per hybridoma fusion
  • +9 more outcomes

Companies that use Creative Biolabs

Customer profile

Segments4 records

Ideal customer profiles4 records

Creative Biolabs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature18 records

Creative Biolabs partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Creative Biolabs competitors and assessment

Company assessment

Direct peers

  • GenScript: GenScript is a leading CRO/CDMO offering custom antibody discovery, gene synthesis, protein engineering, and cell therapy services. It is the closest direct peer to Creative Biolabs given its overlapping focus on antibody/phage display platforms and custom research services for pharma and academic clients.
  • Abcam: Abcam is a major provider of research-grade antibodies, recombinant antibodies, and antibody-related services with strong catalog offerings comparable to Creative Biolabs' recombinant antibody and membrane protein product lines. Both serve academic and pharma researchers globally.
  • Sino Biological: Sino Biological provides recombinant proteins, antibodies, and CRO services for life science research, with a strong catalog of recombinant antibodies and membrane protein reagents. It overlaps with Creative Biolabs in membrane protein targets, recombinant antibody products, and custom services.

Broad incumbents

  • Bio-Techne: Bio-Techne is a large life science tools company offering proteins, antibodies, and reagents across research and diagnostics. While broader and more catalog-focused than Creative Biolabs, it competes in antibody reagents and protein-based services for the same buyer segments.
  • WuXi AppTec: WuXi AppTec is a global CRO/CDMO with extensive capabilities spanning discovery, preclinical, and clinical services for biologics and small molecules. It is a much larger incumbent that competes with Creative Biolabs on antibody discovery and biologics manufacturing services.
  • Charles River Laboratories: Charles River Laboratories is a major CRO offering discovery, safety assessment, and manufacturing services including biologics and cell therapy support. It competes broadly with Creative Biolabs' preclinical CRO services and CDMO offerings.
  • Lonza: Lonza is a leading global CDMO with biologics and cell/gene therapy manufacturing capabilities. Its GMP manufacturing and viral vector production overlap directly with Creative Biolabs' emerging GMP CAR-T and viral vector services.
  • Cell Signaling Technology: Cell Signaling Technology is an established antibody reagent company with strong catalog offerings for signaling and post-translational modification targets. It overlaps with Creative Biolabs' antibody catalog and PTM-specific antibody discovery services.
  • Thermo Fisher Scientific: Thermo Fisher is the largest life sciences tools and CRO/CDMO provider through Patheon and PPD, offering end-to-end services from discovery through clinical manufacturing. It is a broad incumbent peer competing across Creative Biolabs' service categories.

Emerging players

  • ProMab Biotechnologies: ProMab is a smaller CRO specializing in custom monoclonal antibody development, hybridoma, and recombinant antibody services. It is an emerging peer competing directly in the same niche custom antibody discovery market as Creative Biolabs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Creative Biolabs social profiles

Digital presence

Creative Biolabs compliance and trust

Trust signal

Compliance1 record

Creative Biolabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Creative Biolabs leadership team

Management profile

Number of profiles

Creative Biolabs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Creative Biolabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Creative Biolabs

What does Creative Biolabs do?

Creative Biolabs is a contract research organization (CRO) that delivers custom antibody discovery, engineering, characterization, and manufacturing services for pharmaceutical, biotechnology, and academic clients. The company offers proprietary platforms spanning phage display, hybridoma (Hyperdoma™, Hi-Affi Hybridoma™), yeast display, single B cell sorting, and transgenic mice systems to generate monoclonal, bispecific, and single domain antibodies, complemented by gene therapy, cell therapy, viral vector, biosimilar, and lipid nanoparticle delivery services.

Is Creative Biolabs a public or private company?

Creative Biolabs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Creative Biolabs founded?

Creative Biolabs was founded in 2014. It employs 11 to 50 people.

Where is Creative Biolabs based?

Creative Biolabs is headquartered in New York, United States, in the North America region.

How does Creative Biolabs make money?

Two revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are product Sales.

Who are Creative Biolabs's main competitors?

Direct peers on record are GenScript, Abcam and Sino Biological. Broad incumbents are Bio-Techne, WuXi AppTec, Charles River Laboratories, Lonza, Cell Signaling Technology and Thermo Fisher Scientific. ProMab Biotechnologies is listed as an emerging player.

Does Creative Biolabs have an API?

No public API is recorded for Creative Biolabs.

What industry is Creative Biolabs in?

Creative Biolabs's product category is Contract Research Services (Antibody Discovery & Biologics). Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageCreative Biolabs Highlights Complementary Blood-Brain Barrier Models for CNS Drug ResearchCreative Biolabs highlights two complementary human-cell-based BBB models—a co-culture system and a 3D spheroid—for CNS drug research. The models serve different purposes, with co-culture focusing on barrier properties and spheroids on spatial organization, neither independently predicting human brain exposure.24-7 Press ReleaseCreative Biolabs Highlights iPSC Neural Models for Drug DiscoveryCreative Biolabs highlights iPSC-derived neuronal differentiation, disease-relevant neural models, and microfluidic platforms to support neurological research and early drug evaluation. The company offers services for Parkinson's and ALS studies, including gradient-generating and membrane-separated devices. Researchers are advised to validate models before expanding screening.24-7 Press ReleaseBeyond Stronger Binding: Creative Biolabs Supports Antibody Developability with AICreative Biolabs offers AI-assisted antibody design and early developability assessment, including multispecific design, affinity maturation, and aggregation/viscosity prediction. The services aim to help research teams prioritize which antibody candidates merit further experimental investment. The company invites project-specific inquiries for custom assessments.24-7 Press ReleaseCreative Biolabs Addresses Blind Spots in Single-Cell RNA ResearchCreative Biolabs highlights single-cell RNA sequencing, single-nucleus RNA sequencing, and single-molecule FISH to address cellular heterogeneity. The services differ by sample type: whole-cell for viable cells, nuclear for frozen tissues, and FISH for targeted RNA localization. Researchers are advised to select methods based on sample suitability and research objectives.FinancialContent Business PageCreative Biolabs Highlights Human-Relevant Cell Models and Immune Assays for Drug DiscoveryCreative Biolabs offers directed iPSC differentiation, THP-1 macrophage modeling, and immune checkpoint assays to support drug discovery. The services aim to address limitations in conventional in vitro models, including restricted cellular diversity and incomplete functional maturity. Researchers can explore customized workflows for disease modeling and immunology studies.Business & FinancialCreative Biolabs Highlights Human-Relevant Cell Models And Immune Assays For Drug DiscoveryCreative Biolabs offers directed iPSC differentiation, THP-1-based macrophage models, and immune checkpoint assays for drug discovery. The services aim to address limitations in conventional models, including restricted cellular diversity and incomplete immune representation. Researchers can explore customized workflows for disease modeling and therapeutic evaluation.24-7 Press ReleaseCreative Biolabs Highlights Complement Assays and Microfluidic Droplet Generation ToolsCreative Biolabs highlights its CH50 functional test kit and hemolysis inhibition profiling service for complement pathway assessment, plus a flow-focusing microfluidic chip for droplet generation. The products are intended for research use only, supporting inhibitor characterization and compartmentalized workflows.Business & FinancialCreative Biolabs Connects Antibody Engineering With C1q And Fcrn Binding AnalysisCreative Biolabs offers antibody engineering and Fc binding analysis services, including C1q and FcRn binding assays, to support therapeutic antibody development. The company provides humanization, deimmunization, Fc engineering, and glycoengineering, along with ELISA and real-time label-free binding platforms. These services help researchers evaluate complement and recycling properties for candidate selection.24-7 Press ReleaseCreative Biolabs Launches OMV & Exosome-Boosted CAR-T Development Platform for Solid Tumor ResearchCreative Biolabs launched an integrated OMV and exosome-boosted CAR-T development platform to address solid-tumor barriers. The platform combines bacterial outer membrane vesicles and mammalian exosomes for stroma remodeling and T-cell persistence, with cargo-loading capabilities. It aims to enable parallel investigation of multiple barriers in preclinical models.24-7 Press ReleaseCreative Biolabs Highlights Tumor Organoid Co-Culture Models for CAR-T ResearchCreative Biolabs highlights its tumor organoid and immune cell co-culture services for studying CAR-T cell activity in 3D tumor models. The services include organoid construction, co-culture with CAR-T or other immune cells, and functional assays for tumor cell survival, killing, proliferation, and cytokine release. Results are for preclinical research only and do not fully reproduce in vivo tumor microenvironment components.